We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current DTCFF market cap is 21.72M. The company's latest EPS is CAD -0.2769 and P/E is -1.66.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -179k | -974k | -2.97M | -2.37M | -12.82M |
| Net Income | -673k | -2.86M | -7.34M | -6.76M | -13.19M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 1.91M | 5.61M | 720k | 3.53M | 477k |
| Total Liabilities | 48k | 122k | 1.11M | 1.97M | 4.06M |
| Total Equity | 1.86M | 5.49M | -388k | 1.57M | -3.59M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -133k | -2.29M | -6.04M | -7.66M | -4.29M |
| Investing | -46k | N/A | N/A | -66k | -203k |
| Financing | 2.04M | 5.88M | 1.1M | 10.01M | 1.76M |
| Market Cap | 21.72M |
| Price to Earnings Ratio | -1.66 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 383.33 |
| Price to Book Ratio | -6.11 |
| Dividend Yield | - |
| Shares Outstanding | 47.65M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 100 |
| 52 Week Change | -72.38% |
| 52 Week High | 1.738 |
| 52 Week Low | 0.2732 |
| Spread (Intraday) | 0.64 (81.35%) |
| Company Name | Defence Therapeutics Inc (QB) |
| Address |
1680 - 200 burrard street vancouver, british columbia V6C 3L6 |
| Website | https://www.defencetherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
